Stocktoria
Compass Therapeutics, Inc. CMPX
Nasdaq · XNAS · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2020-11-13
Chart by TradingView
3/9
Piotroski F — financial health
6.28
Altman Z″ — distress risk · safe
—
Dividend payout · no dividend
Financials & ratios (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Financials | |||||
| Revenue | $0 | $850,000 | $0 | — | — |
| Operating income | -$72.8M | -$56.6M | -$50.4M | -$41.7M | -$81.9M |
| Net income | -$66.5M | -$49.4M | -$42.5M | -$39.2M | -$82.2M |
| Operating cash flow | -$49.1M | -$44.9M | -$40.6M | -$34.1M | -$19.7M |
| Free cash flow | -$49.2M | -$44.9M | -$40.6M | -$34.3M | -$21.2M |
| Total assets | $219.6M | $140.4M | $156.9M | $199.6M | $153.8M |
| Total liabilities | $22.8M | $15.2M | $8.3M | $18.0M | $13.7M |
| Shareholders' equity | $196.8M | $125.2M | $148.5M | $181.6M | $140.1M |
| Ratios | |||||
| Operating margin | — | -6661.8% | — | — | — |
| Net margin | — | -5808.8% | — | — | — |
| FCF margin | — | -5282.2% | — | — | — |
| Return on assets | -30.3% | -35.2% | -27.1% | -19.6% | -53.4% |
| Return on equity | -33.8% | -39.4% | -28.6% | -21.6% | -58.7% |
| Debt / equity | — | — | — | — | 0.00× |
| Current ratio | 15.02 | 14.96 | 19.73 | 12.05 | 13.84 |
| Revenue growth | -100.0% | — | — | — | — |
Why these scores methodology →
Piotroski F-score: 3/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: 6.28 (safe)
- Working capital / assets 0.892
- Retained earnings / assets -1.964
- EBIT / assets -0.332
- Equity / liabilities 8.632
Sector peers
VFS · TM · HMC · SONY · AAPL · XOM · all Manufacturing →
Source: SEC EDGAR filings · CIK 0001738021 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.